证券之星消息，截至2025年8月4日收盘，春立医疗(688236)报收于21.77元，上涨2.4%，换手率1.15%， 成交量3.33万手，成交额7205.17万元。 8月4日的资金流向数据方面，主力资金净流入373.26万元，占总成交额5.18%，游资资金净流出0.02万 元，散户资金净流出373.24万元，占总成交额5.18%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-04 | 21.77 | 2.40% | 373.26万 | 5.18% | -168.00 | 0.00% | -373.24万 | -5.18% | | 2025-08-01 | 21.26 | -3.67% | -1068.88万 | -15.67% | -207.65万 | -3.04% | 1276.52万 | 18.72% | | 2025-07-31 | 22.12 -1.69% | | ...

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 21.77 yuan, with a 2.40% increase, resulting in a rolling PE ratio of 65.31 times and a total market value of 8.35 billion yuan [1] - The average PE ratio for the medical device industry is 54.32 times, with a median of 38.11 times, placing Chunzhi Medical at the 90th position in the industry ranking [1] - As of March 31, 2025, Chunzhi Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.07 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1]

Group 1 - The stock price of Chunli Medical as of July 31, 2025, closed at 22.12 yuan, down by 0.38 yuan, representing a decline of 1.69% from the previous trading day [1] - The trading volume on that day was 30,700 lots, with a transaction value of 0.69 billion yuan, and the stock experienced a fluctuation of 5.56% [1] - Chunli Medical specializes in the research, development, production, and sales of orthopedic medical devices, covering areas such as joints, spine, and trauma [1] Group 2 - The company announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 0.49 yuan per 10 shares, with the record date set for July 31 [1] - On July 31, Chunli Medical experienced a net outflow of main funds amounting to 8.61 million yuan, which accounted for 0.13% of its circulating market value [1]

最近三个交易日，28日-30日，春立医疗分别获融资买入0.15亿元、0.06亿元、0.12亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 7月30日，沪深两融数据显示，春立医疗获融资买入额0.12亿元，居两市第1213位，当日融资偿还额0.07 亿元，净买入560.18万元。 本文源自：金融界 作者：智投君 ...

Group 1 - The article provides a list of companies listed on the Hong Kong stock market along with their dividend distribution dates and shareholder meeting dates [1][4][5] - Notable companies mentioned include China Railway, Green Town China, and Budweiser APAC, which are scheduled for dividend payments [4][5] - The document outlines various companies' actions regarding capital increases and dividend distributions, indicating ongoing corporate activities in the market [4][5]

证券之星消息，截至2025年7月30日收盘，春立医疗(688236)报收于22.5元，下跌0.88%，换手率 1.11%，成交量3.19万手，成交额7327.56万元。 7月30日的资金流向数据方面，主力资金净流入157.48万元，占总成交额2.15%，游资资金净流入43.71 万元，占总成交额0.6%，散户资金净流出201.19万元，占总成交额2.75%。 春立医疗2025年一季报显示，公司主营收入2.3亿元，同比上升3.6%；归母净利润5807.11万元，同比上 升5.2%；扣非净利润5269.81万元，同比上升7.81%；负债率17.11%，投资收益321.7万元，财务费 用-416.65万元，毛利率66.69%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与 销售。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： | 指标 | 春立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 86.3亿元 | 115.74亿元 | 42 122 | | 净资产 | 28.79亿元 | 39.18亿元 | 52 12 ...

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock price closed at 22.7 yuan, with a PE ratio of 68.10, marking a new low in 301 days, and a total market capitalization of 8.707 billion yuan [1] - The average PE ratio for the medical device industry is 55.28, with a median of 38.06, positioning Chunzhi Medical at the 89th rank within the industry [1] - As of March 31, 2025, Chunzhi Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, reflecting a year-on-year growth of 5.20%, with a gross profit margin of 66.69% [1]

Core Viewpoint - Spring Medical (688236) has adjusted its 2024 profit distribution cash dividend total to RMB 18,727,390.80 (including tax), with a cash dividend of RMB 0.049 per share, reflecting a minor change due to share buybacks [2][3][5]. Trading Information Summary - On July 25, Spring Medical's stock closed at RMB 22.4, up 7.49%, with a turnover rate of 1.99%, trading volume of 57,300 shares, and a transaction amount of RMB 128 million [1]. - The fund flow on the same day showed a net outflow of RMB 847.16 million from main funds, accounting for 6.63% of the total transaction amount, while retail investors had a net inflow of RMB 934.27 million, representing 7.31% of the total [2][5]. Company Announcement Summary - Spring Medical announced an adjustment in the total cash dividend for 2024 from RMB 18,752,317.40 (including tax) to RMB 18,727,390.80 (including tax) due to changes in the number of shares participating in the profit distribution [2][5]. - The company will distribute a cash dividend of RMB 0.49 per 10 shares (including tax), with the actual number of shares participating in the distribution being 382,191,649 shares [2][3]. Legal Opinion Summary - A special legal opinion from Beijing Wanshang Tianqin Law Firm confirmed that the differentiated dividend distribution for A-shares complies with relevant laws and regulations, and the impact on the ex-dividend price is minimal, below 1% [4].

Group 1 - The stock price of Chunli Medical (688236) closed at 22.4 yuan on July 25, 2025, up 15.76% from last week's 19.35 yuan, with a peak price of 23.67 yuan during the week, marking a near one-year high [1] - The total market capitalization of Chunli Medical is 8.592 billion yuan, ranking 42nd out of 126 in the medical device sector and 2009th out of 5148 in the A-share market [1] - The company announced adjustments to the 2024 profit distribution cash dividend total, changing it from 18,752,317.40 yuan (tax included) to 18,727,390.80 yuan (tax included) due to changes in the number of shares in the repurchase special securities account [1][3] Group 2 - The annual equity distribution for 2024 will provide a cash dividend of 0.049 yuan per share (tax included), with the record date set for July 31, 2025, and the ex-dividend date and cash dividend payment date on August 1, 2025 [2] - The actual number of shares participating in the distribution is 382,191,649, with a total profit distribution amount of 18,727,390.80 yuan (tax included) [2] - Different tax rates will apply to individual shareholders and securities investment funds based on their holding periods, with QFII shareholders and Hong Kong market investors subject to a 10% withholding tax [2]

Core Viewpoint - The legal opinion issued by Beijing Wan Shang Tian Qin Law Firm confirms that the differentiated dividend distribution plan of Beijing Chunli Zhengda Medical Device Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [4][10]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's 2024 profit distribution plan, which proposes a cash dividend of 0.49 RMB per 10 shares, with no stock dividends or capital reserve transfers [6][8]. - The total number of shares participating in the distribution is 382,191,649, which includes 287,051,149 A shares and 95,140,500 H shares, after excluding the repurchased shares [8][9]. - The company has repurchased 1,376,851 A shares, accounting for approximately 0.4774% of the total A shares, which do not participate in the dividend distribution [6][8]. Group 2: Legal Compliance and Verification - The law firm conducted thorough verification of the documents and materials provided by the company, ensuring their authenticity and completeness [2][3]. - The legal opinion is strictly based on Chinese laws and regulations, and does not cover any non-legal professional matters such as accounting or finance [3][4]. - The law firm confirms that the differentiated dividend distribution aligns with the provisions of the Company Law, Securities Law, and relevant regulatory guidelines [4][10]. Group 3: Impact on Stock Price - The differentiated dividend distribution is expected to have a minimal impact on the A-share ex-dividend reference price, with the absolute value of the impact being less than 1% [10]. - The calculated A-share ex-dividend reference price is approximately 18.7212 RMB per share, based on the last closing price and the cash dividend [9][10].